orserdu
stemline therapeutics b.v. - elacestrant - neoplasias de la mama - terapia endocrina - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.
clotrimazol gine-canesmed 20 mg/g crema vaginal efg
bayer hispania s.l. - clotrimazol - crema vaginal - 20 mg/g - clotrimazol 20 mg - clotrimazol
gine-canesten 100 mg/g crema vaginal
bayer hispania s.l. - clotrimazol - crema vaginal - 100 mg/g - clotrimazol 100 mg - clotrimazol
gine-canesten 20 mg/g crema vaginal
bayer hispania s.l. - clotrimazol - crema vaginal - 20 mg/g - clotrimazol 20 mg - clotrimazol
clotrimazol gine-canesmed 100 mg comprimidos vaginales efg
bayer hispania s.l. - clotrimazol - comprimido vaginal - 100 mg - clotrimazol 100 mg - clotrimazol
clotrimazol gine-canesmed 500 mg comprimido vaginal efg
bayer hispania s.l. - clotrimazol - comprimido vaginal - 500 mg - clotrimazol 500 mg - clotrimazol
gine-canesten 500 mg comprimido vaginal
bayer hispania s.l. - clotrimazol - comprimido vaginal - 500 mg - clotrimazol 500 mg - clotrimazol
gine-canesten 100 mg comprimidos vaginales
bayer hispania s.l. - clotrimazol - comprimido vaginal - 100 mg - clotrimazol 100 mg - clotrimazol
gine-canesten 500 mg capsula vaginal blanda
bayer hispania s.l. - clotrimazol - cÁpsula vaginal blanda - 500 mg - clotrimazol 500 mg - clotrimazol
implanon nxt 68 mg implante
organon salud s.l. - etonogestrel - implante - 68 mg - etonogestrel 68 mg - etonogestrel